Meinolf Karthaus

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

Johan Maertens, Issam Raad, Kieren A. Marr et al. · The Lancet · 2015 · 972 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type <i>KRAS</i> Exon 2 Metastatic Colorectal Cancer

Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus et al. · Journal of Clinical Oncology · 2014 · 632 citations

Medicine, Oncology, Pharmacology +12

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano, Jon Salmanton‐García, Francesco Marchesi et al. · Journal of Hematology & Oncology · 2021 · 318 citations · Full text

Medicine, Hematology, Infectious Diseases +13

Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

Johan Maertens, Galia Rahav, Dong‐Gun Lee et al. · The Lancet · 2021 · 276 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program

Armando Santoro, Mary O’Brien, Rolf A. Stahel et al. · Journal of Thoracic Oncology · 2008 · 253 citations

Medicine, Oncology, Pharmacology +13